Atea Pharmaceuticals (AVIR) EPS (Basic): 2020-2022
Historic EPS (Basic) for Atea Pharmaceuticals (AVIR) over the last 3 years, with Dec 2022 value amounting to -$0.41.
- Atea Pharmaceuticals' EPS (Basic) fell 129.08% to -$0.41 in Q4 2022 from the same period last year, while for Dec 2022 it was -$1.40, marking a year-over-year decrease of 195.89%. This contributed to the annual value of -$2 for FY2024, which is 22.70% down from last year.
- Latest data reveals that Atea Pharmaceuticals reported EPS (Basic) of -$0.41 as of Q4 2022, which was down 310.00% from -$0.10 recorded in Q3 2022.
- Atea Pharmaceuticals' 5-year EPS (Basic) high stood at $2.62 for Q4 2020, and its period low was -$1.74 during Q3 2020.
- Moreover, its 3-year median value for EPS (Basic) was -$0.34 (2021), whereas its average is $0.05.
- Its EPS (Basic) has fluctuated over the past 5 years, first spiked by 105.00% in 2021, then crashed by 2,000.00% in 2022.
- Quarterly analysis of 3 years shows Atea Pharmaceuticals' EPS (Basic) stood at $2.62 in 2020, then plummeted by 46.18% to $1.41 in 2021, then slumped by 129.08% to -$0.41 in 2022.
- Its last three reported values are -$0.41 in Q4 2022, -$0.10 for Q3 2022, and -$0.38 during Q2 2022.